TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5747-5752

  Li, Hui ^a   Zhang, Yi ^a   Zhang, Yue ^a   Bai, Xue ^a   Peng, Yang ^a   He, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin D1; Cyclin E; Immunohistochemistry; NSCLC; TRIM31

Indexed keywords

CYCLIN D1; CYCLIN E; PROTEIN; TRIM31 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BRONCHIAL EPITHELIAL HBE CELL LINE; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CELL GROWTH; CELL INVASION; CELL LINE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLIN D1; CYCLIN E; DOWN-REGULATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 84904729436     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1763-x     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11-30.
2. Li H, Wang RM, Liu SG, Zhang JP, Luo JY, Zhang BJ, et al. Abnormal expression of FLOT1 correlates with tumor progression and poor survival in patients with non-small cell lung cancer. Tumour Biol. 2013. doi:10.1007/s13277-013-1434-3.
3. Wang L, Meng L, Wang XW, Ma GY, Chen JH. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2013. doi:10.1007/s13277-013-1255-4.
4. Dong QZ, Wang Y, Dong XJ, Li ZX, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857-65.
5. Dong QZ, Wang Y, Tang ZP, Fu L, et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013;182:954-64.
6. Dong QZ, Zhao Y, Liu Y, Wang Y, et al. Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci. 2010;101:1562-9.
7. Sugiura T, Miyamoto K. Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein. J Cell Biochem. 2008;105:1081-91.
8. Watanabe M, Tsukiyama T, Hatakeyama S. TRIM31 interacts with p52(Shc) and inhibits Src-induced anchorage-independent growth. Biochem Biophys Res Commun. 2009;388:422-7.
9. Zhang M, Luo W, Huang B, Liu Z, et al. Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression. PLoS One. 2013;8:e79173.
10. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994;79:573-82. (Pubitemid 24363801)
11. Vizkeleti L, Ecsedi S, Rakosy Z, Orosz A, et al. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol. 2012;33:2189-99.
12. Liu Y, Wang L, Lin XY, Wang J, et al. The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells. Tumour Biol. 2013;34:1641-50.
13. Liu J, Liao Q, Zhang Y, Sun S, Zhong C, Liu X. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2012;33(5):1467-76. doi:10.1007/s13277-012-0397-0.
14. Musgrove EA, Caldon CE, Barraclough J, Stone A, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558-72.
15. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.
16. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J. 1999;13:773-80. (Pubitemid 29220690)
17. Gao S, Ma JJ, Lu C. Prognostic value of cyclin E expression in breast cancer: a meta-analysis. Tumour Biol. 2013;34(6):3423-30. doi:10.1007/s13277- 013-0915-8.
18. Huang LN, Wang DS, Chen YQ, Li W, et al. Meta-analysis for cyclin E in lung cancer survival. Clin Chim Acta. 2012;413:663-8.
19. Zhang LQ, Jiang F, Xu L, Wang J, et al. The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer. 2012;13:188-95.
20. Ravichandran KS. Signaling via Shc family adapter proteins. Oncogene. 2001;20:6322-30. (Pubitemid 32977841)
21. Patrussi L, Savino MT, Pellegrini M, Paccani SR, et al. Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival. Oncogene. 2005;24:2218-28. (Pubitemid 40516588)
22. Peeper DS, Upton TM, Ladha MH, Neuman E, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 1997;386:177-81. (Pubitemid 27131445)